1 A nutritional condition produced by a deficiency of magnesium in the diet, characterized by anorexia, nausea, vomiting, lethargy, and weakness. 2  Symptoms are paresthesias, muscle cramps, irritability, decreased attention span, and mental confusion, possibly requiring months to appear.
Bravecto (fluralaner) is a systemic antiparasitic drug introduced to the veterinary market by Merck in 2014. A 7 March 2014 study published in the journal Parasites & Vectors (based upon a study of 32 beagles treated with fluralaner) observed no serious adverse side effects attributed to the medication:
There are two new FDA-approved products on the market this year for dogs: Nexgard and Bravecto. Nexgard is made by Merial, Bravecto is made by Merck, and they are in the same chemical family. These drugs work by causing uncontrolled activity in the nervous system of fleas and ticks, leading to death. Nexgard was released to the market first, followed by Bravecto.